Alkermes execs say they’re flummoxed by embarrassing FDA drug refusal; stock plunges

The regulator said it wouldn’t even review the company’s depression drug application, saying there wasn’t enough evidence that it worked.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.